| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sato T et al. | In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. | 2011 | Antimicrob. Agents Chemother. | pmid:21220530 |
| Lounis N et al. | ATP synthase inhibition of Mycobacterium avium is not bactericidal. | 2009 | Antimicrob. Agents Chemother. | pmid:19738016 |
| Hamasuna R et al. | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. | 2009 | Antimicrob. Agents Chemother. | pmid:19738019 |
| Maurin M and Raoult D | In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8109928 |
| O'Hara K and Yamamoto K | Reaction of roxithromycin and clarithromycin with macrolide-inactivating enzymes from highly erythromycin-resistant Escherichia coli. | 1996 | Antimicrob. Agents Chemother. | pmid:8849224 |
| Giacometti A et al. | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. | 2007 | Antimicrob. Agents Chemother. | pmid:17220421 |
| Ishida K et al. | In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. | 1994 | Antimicrob. Agents Chemother. | pmid:8031048 |
| Vermot D et al. | Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis. | 1996 | Antimicrob. Agents Chemother. | pmid:8851620 |
| Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Kato M et al. | Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. | 2000 | Antimicrob. Agents Chemother. | pmid:10898707 |
| Xu YF et al. | and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. | 2017 | Antimicrob. Agents Chemother. | pmid:28320722 |
| Geng X et al. | The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. | 2017 | Antimicrob. Agents Chemother. | pmid:28242673 |
| Waites KB et al. | In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. | 1988 | Antimicrob. Agents Chemother. | pmid:2973283 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Wakabayashi H et al. | Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. | 2009 | Antimicrob. Agents Chemother. | pmid:19451301 |
| Rastogi N et al. | Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667250 |
| Lazard T et al. | Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. | 1993 | Antimicrob. Agents Chemother. | pmid:8215285 |
| Kosowska-Shick K et al. | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. | 2007 | Antimicrob. Agents Chemother. | pmid:17116666 |
| Kim IS et al. | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. | 2007 | Antimicrob. Agents Chemother. | pmid:17116681 |
| Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
| Goldman RC et al. | Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. | 1994 | Antimicrob. Agents Chemother. | pmid:7979278 |
| Roblin PM et al. | Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. | 1994 | Antimicrob. Agents Chemother. | pmid:7979292 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Cynamon MH and Klemens SP | Activity of azithromycin against Mycobacterium avium infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1329622 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Fernandes PB et al. | New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. | 1989 | Antimicrob. Agents Chemother. | pmid:2523688 |
| Sassa K et al. | Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. | 1999 | Antimicrob. Agents Chemother. | pmid:10543765 |
| Beeton ML et al. | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. | 2009 | Antimicrob. Agents Chemother. | pmid:19273669 |
| Koh WJ et al. | Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. | 2013 | Antimicrob. Agents Chemother. | pmid:23478956 |
| Rimbara E et al. | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. | 2008 | Antimicrob. Agents Chemother. | pmid:18606842 |
| Bolhuis MS et al. | Clarithromycin significantly increases linezolid serum concentrations. | 2010 | Antimicrob. Agents Chemother. | pmid:20837753 |
| Tsuda T et al. | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. | 2008 | Antimicrob. Agents Chemother. | pmid:18212111 |
| Jesus FP et al. | In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25001300 |
| Khan R et al. | T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. | 2004 | Antimicrob. Agents Chemother. | pmid:15328128 |
| Hoffner SE et al. | Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. | 1993 | Antimicrob. Agents Chemother. | pmid:8392308 |
| van Zanten SJ et al. | Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. | 2003 | Antimicrob. Agents Chemother. | pmid:12821476 |
| Nash KA et al. | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. | 2009 | Antimicrob. Agents Chemother. | pmid:19171799 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Mor N and Heifets L | MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. | 1993 | Antimicrob. Agents Chemother. | pmid:8431006 |
| Klopman G et al. | Anti-Mycobacterium avium activity of quinolones: in vitro activities. | 1993 | Antimicrob. Agents Chemother. | pmid:8239587 |
| Fong IW et al. | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. | 2002 | Antimicrob. Agents Chemother. | pmid:12121899 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Ménard A et al. | PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:11897613 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Hotomi M et al. | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. | 2007 | Antimicrob. Agents Chemother. | pmid:17698631 |
| Berg HF et al. | Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. | 2004 | Antimicrob. Agents Chemother. | pmid:15504839 |
| Brown BA et al. | Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. | 1992 | Antimicrob. Agents Chemother. | pmid:1317144 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Bastian S et al. | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | 2011 | Antimicrob. Agents Chemother. | pmid:21135185 |
| Rastogi N and Labrousse V | Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1828135 |
| Luna-Herrera J et al. | Antituberculosis activity of clarithromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:8593004 |
| Ellis LC et al. | Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. | 1995 | Antimicrob. Agents Chemother. | pmid:8593025 |
| Truffot-Pernot C et al. | Clarithromycin is inactive against Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:8593032 |
| Heifets L et al. | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8031351 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Mathis A et al. | Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis. | 2005 | Antimicrob. Agents Chemother. | pmid:16048933 |
| Cohen Y et al. | Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. | 1992 | Antimicrob. Agents Chemother. | pmid:1332586 |
| Dai G et al. | Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:16048962 |
| Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
| Shinkai M et al. | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. | 2006 | Antimicrob. Agents Chemother. | pmid:16641444 |
| Bermudez LE et al. | Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice. | 2012 | Antimicrob. Agents Chemother. | pmid:22615290 |
| Anton E et al. | Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. | 2015 | Antimicrob. Agents Chemother. | pmid:26711765 |
| Truffot-Pernot C et al. | Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1834015 |
| Klemens SP and Cynamon MH | Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7979271 |
| Klemens SP et al. | Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1336945 |
| Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Ishikawa C et al. | Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. | 2009 | Antimicrob. Agents Chemother. | pmid:19258275 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| Alper CM et al. | Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae in the chinchilla. | 1996 | Antimicrob. Agents Chemother. | pmid:8843299 |
| Rana KZ et al. | Clarithromycin does not affect phosphorylation of zidovudine in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8843311 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Bermudez LE et al. | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. | 2007 | Antimicrob. Agents Chemother. | pmid:17296742 |
| Floyd-Reising S et al. | In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. | 1987 | Antimicrob. Agents Chemother. | pmid:2955742 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Fernandes PB et al. | Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. | 1987 | Antimicrob. Agents Chemother. | pmid:2957954 |
| Alder JD et al. | Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. | 1998 | Antimicrob. Agents Chemother. | pmid:9736568 |
| Gillum JG et al. | Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. | 1996 | Antimicrob. Agents Chemother. | pmid:8807068 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Bernut A et al. | In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. | 2014 | Antimicrob. Agents Chemother. | pmid:24798271 |
| Spyridaki I et al. | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. | 2009 | Antimicrob. Agents Chemother. | pmid:19332671 |
| Parra-Ruiz J et al. | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. | 2010 | Antimicrob. Agents Chemother. | pmid:20696880 |
| Jones RN et al. | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. | 2010 | Antimicrob. Agents Chemother. | pmid:20660671 |
| Wenisch C et al. | Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. | 1996 | Antimicrob. Agents Chemother. | pmid:8878577 |
| Koh WJ et al. | Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. | 2013 | Antimicrob. Agents Chemother. | pmid:23183432 |
| Kosowska-Shick K et al. | Comparative antipneumococcal activities of sulopenem and other drugs. | 2009 | Antimicrob. Agents Chemother. | pmid:19307366 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |